Fulcrum Therapeutics (FULC) News Today $6.25 -0.26 (-3.99%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$6.12 -0.14 (-2.16%) As of 05/21/2025 05:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FULC Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Purchased by Suvretta Capital Management LLCSuvretta Capital Management LLC increased its stake in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 182.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,338,466 shares of the company's stMay 19 at 7:38 AM | marketbeat.comFulcrum Therapeutics (NASDAQ:FULC) Upgraded at Cantor FitzgeraldMay 18, 2025 | americanbankingnews.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Acquired by Graham Capital Management L.P.Graham Capital Management L.P. increased its holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 58.9% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 144,942 shares of the company's stock after buying an additional 53,726 shares during theMay 17, 2025 | marketbeat.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $6.67 Consensus Price Target from AnalystsMay 17, 2025 | americanbankingnews.comCantor Fitzgerald Upgrades Fulcrum Therapeutics (FULC)May 16, 2025 | msn.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Consensus Rating of "Reduce" by AnalystsFulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) has received a consensus rating of "Reduce" from the seven analysts that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and six have given a hold rating to the company. The averaMay 16, 2025 | marketbeat.comCAMP4 Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial ResultsMay 15, 2025 | nasdaq.comCisco upgraded, CoreWeave downgraded: Wall Street's top analyst callsMay 15, 2025 | finance.yahoo.comBridgeway Capital Management LLC Purchases New Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)Bridgeway Capital Management LLC acquired a new stake in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 140,000 shares of the company'May 14, 2025 | marketbeat.comFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 9, 2025 | globenewswire.comFulcrum Therapeutics (FULC) Projected to Post Earnings on MondayFulcrum Therapeutics (NASDAQ:FULC) will be releasing its Q1 2025 earnings before the market opens on Monday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-12-fulcrum-therapeutics-inc-stock/)May 7, 2025 | marketbeat.comFulcrum Therapeutics (NASDAQ:FULC) Announces Earnings Results, Beats Estimates By $0.01 EPSFulcrum Therapeutics (NASDAQ:FULC - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.01.May 5, 2025 | marketbeat.comBoothbay Fund Management LLC Reduces Stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)Boothbay Fund Management LLC lessened its stake in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 60.6% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 59,533 shares of the company's stoMay 5, 2025 | marketbeat.comSusquehanna Fundamental Investments LLC Purchases Shares of 213,213 Fulcrum Therapeutics, Inc. (NASDAQ:FULC)Susquehanna Fundamental Investments LLC acquired a new stake in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 213,213 shares of the company's stock,May 4, 2025 | marketbeat.comEarnings call transcript: Fulcrum Therapeutics Q1 2025 reveals improved net lossMay 3, 2025 | uk.investing.comFulcrum Therapeutics, Inc. (FULC) Q1 2025 Earnings Call TranscriptMay 2, 2025 | seekingalpha.comFulcrum therapeutics targets key data from PIONEER trial in Q3 2025May 2, 2025 | msn.comQ1 2025 Fulcrum Therapeutics Inc Earnings CallMay 2, 2025 | finance.yahoo.comFulcrum Therapeutics Inc (FULC) Q1 2025 Earnings Call Highlights: Strategic Cost Reductions and ...May 2, 2025 | finance.yahoo.comFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025May 1, 2025 | globenewswire.com2FULC : Uncovering Potential: Fulcrum Therapeutics's Earnings PreviewApril 30, 2025 | benzinga.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Acquired by Adage Capital Partners GP L.L.C.Adage Capital Partners GP L.L.C. increased its holdings in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 50.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,000,000 shares of the company's stock aftApril 30, 2025 | marketbeat.comFulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ETApril 24, 2025 | globenewswire.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Average Recommendation of "Hold" from BrokeragesFulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) has earned a consensus recommendation of "Hold" from the nine analysts that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, six have assigned a hoApril 21, 2025 | marketbeat.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Sees Large Decrease in Short InterestFulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) was the recipient of a large decrease in short interest in the month of March. As of March 31st, there was short interest totalling 3,730,000 shares, a decrease of 28.5% from the March 15th total of 5,220,000 shares. Based on an average daily trading volume, of 448,900 shares, the days-to-cover ratio is presently 8.3 days. Currently, 7.2% of the shares of the company are short sold.April 20, 2025 | marketbeat.comAltium Capital Management LLC Buys Shares of 111,812 Fulcrum Therapeutics, Inc. (NASDAQ:FULC)Altium Capital Management LLC bought a new position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 111,812 shares of the company's stock, valued at approximatelApril 20, 2025 | marketbeat.comFulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 11, 2025 | globenewswire.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Bought by ADAR1 Capital Management LLCADAR1 Capital Management LLC grew its holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 177.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 196,248 shares of the company's stock after acquiring an aApril 9, 2025 | marketbeat.comNext-generation CRISPR company raises $68 million, zeroes in on first clinical trialMarch 27, 2025 | bizjournals.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Rating of "Hold" from BrokeragesShares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) have been assigned a consensus recommendation of "Hold" from the nine ratings firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, sMarch 25, 2025 | marketbeat.comSimplify Asset Management Inc. Sells 270,600 Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC)Simplify Asset Management Inc. trimmed its holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 77.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 80,714 shares of the company's stock after selling 270,600 sMarch 24, 2025 | marketbeat.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Purchased by Connor Clark & Lunn Investment Management Ltd.Connor Clark & Lunn Investment Management Ltd. raised its stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 176.8% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 367,594 shares of the company's stock after buying an additional 234,81March 20, 2025 | marketbeat.comBristol Myers Acquired MyoKardia Drops Fulcrum Agreement, Ending Cardiomyopathy Research DealMarch 5, 2025 | benzinga.comFulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare ConferenceMarch 4, 2025 | globenewswire.comHC Wainwright Issues Negative Estimate for FULC EarningsFulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) - Research analysts at HC Wainwright cut their Q1 2025 earnings estimates for shares of Fulcrum Therapeutics in a note issued to investors on Wednesday, February 26th. HC Wainwright analyst A. Fein now expects that the company will post earniMarch 1, 2025 | marketbeat.comLeerink Partnrs Has Negative Outlook for FULC Q1 EarningsFulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) - Leerink Partnrs cut their Q1 2025 earnings per share (EPS) estimates for Fulcrum Therapeutics in a report issued on Tuesday, February 25th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings of ($0.35) per sMarch 1, 2025 | marketbeat.comBrokers Set Expectations for FULC FY2029 EarningsFulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) - HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Fulcrum Therapeutics in a report released on Wednesday, February 26th. HC Wainwright analyst A. Fein forecasts that the company will earn ($0.95) per share for the yeaFebruary 28, 2025 | marketbeat.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Average Rating of "Hold" from BrokeragesShares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) have earned a consensus rating of "Hold" from the ten brokerages that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, six have assigned a hold rating and three have assignedFebruary 28, 2025 | marketbeat.comOpCo reiterates Outperform on Fulcrum given bullish vibes ahead of SCD readoutFebruary 27, 2025 | markets.businessinsider.comFulcrum Therapeutics Inc (FULC) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...February 27, 2025 | finance.yahoo.comPiper Sandler Sticks to Its Buy Rating for Fulcrum Therapeutics (FULC)February 27, 2025 | markets.businessinsider.comFulcrum Therapeutics Full Year 2024 Earnings: EPS Misses ExpectationsFebruary 27, 2025 | finance.yahoo.comFulcrum Therapeutics' (FULC) "Neutral" Rating Reaffirmed at HC WainwrightHC Wainwright restated a "neutral" rating and issued a $4.00 price objective on shares of Fulcrum Therapeutics in a report on Wednesday.February 26, 2025 | marketbeat.comFulcrum Therapeutics, Inc. (FULC) Q4 2024 Earnings Call TranscriptFebruary 26, 2025 | seekingalpha.comFulcrum Therapeutics (NASDAQ:FULC) Issues Earnings ResultsFulcrum Therapeutics (NASDAQ:FULC - Get Free Report) released its earnings results on Tuesday. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.03).February 25, 2025 | marketbeat.comFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024February 25, 2025 | markets.businessinsider.comFulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024February 25, 2025 | globenewswire.comFulcrum Digital Champions Intelligence Amplification In AI EvolutionFebruary 24, 2025 | msn.comFulcrum Therapeutics, Inc. (NASDAQ:FULC) Sees Significant Decrease in Short InterestFulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) was the recipient of a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 4,330,000 shares, a decline of 7.3% from the January 15th total of 4,670,000 shares. Based on an average daily trading volume, of 826,100 shares, the days-to-cover ratio is presently 5.2 days.February 18, 2025 | marketbeat.comFulcrum Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call and Webcast on Tuesday, February 25, 2025, at 8:00 a.m. ETFebruary 18, 2025 | globenewswire.com Get Fulcrum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter. Email Address FULC Media Mentions By Week FULC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FULC News Sentiment▼1.060.65▲Average Medical News Sentiment FULC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FULC Articles This Week▼123▲FULC Articles Average Week Get Fulcrum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MESO News Today GPCR News Today JANX News Today EVO News Today SPRY News Today ADPT News Today VERA News Today DYN News Today ANIP News Today OCUL News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FULC) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fulcrum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fulcrum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy FULC Stock Free FULC Stock Alerts